Category: Clinical Trials

Clinical Trials Healthcare & Pharmaceuticals News Oncology

Roche’s Giredestrant Combination Shows Significant Benefit in Advanced ER-Positive Breast Cancer

Roche

Roche’s Phase III evERA study for the investigational drug giredestrant has delivered positive results, showing a significant improvement in progression-free survival for patients with advanced ER-positive breast cancer. The all-oral combination therapy, which was well-tolerated, offers a new, promising treatment option for individuals whose disease has progressed after previous treatments.

Clinical Trials News Weight-loss Drugs

Lilly’s Mounjaro Shows Promising Results in Teens with Type 2 Diabetes

Eli Lilly and Company

Eli Lilly and Company announced positive topline results from its SURPASS-PEDS Phase 3 trial for Mounjaro (tirzepatide). The study, which evaluated the GIP/GLP-1 dual receptor agonist in children and adolescents with type 2 diabetes, demonstrated substantial and statistically significant improvements in blood sugar control and weight management, with a safety profile consistent with adult studies.

Clinical Trials News Weight-loss Drugs

Novo Nordisk Unveils Promising Phase 3 Data for Cagrilintide, a Novel Amylin Analogue for Obesity, Advancing to New Clinical Program

novo nordisk

Novo Nordisk has unveiled compelling phase 3 data for its next-generation obesity drug, cagrilintide, at the EASD 2025 congress. The novel amylin analogue demonstrated a significant 11.8% average body weight reduction over 68 weeks, far surpassing the placebo group. These promising results have prompted the company to advance cagrilintide into a new dedicated clinical program, RENEW, set to begin later this year.

Clinical Trials Healthcare & Pharmaceuticals News

Amgen and Kyowa Kirin Announce Positive Top-Line Results from Rocatinlimab Phase 3 Study for Atopic Dermatitis

amgen

Amgen and Kyowa Kirin announced positive top-line results from the ASCEND Phase 3 long-term study for rocatinlimab, an investigational treatment for adults and adolescents with moderate to severe atopic dermatitis. The study demonstrated a continued therapeutic benefit and a consistent safety profile, showing sustained improvements in skin clearance and itch reduction at one year.

Clinical Trials News Oncology

AstraZeneca’s Tagrisso Combination Therapy Sets New Survival Benchmark in Advanced Lung Cancer

AstraZeneca

hase III trial called FLAURA2 has demonstrated that the combination of AstraZeneca’s drug, Tagrisso, with chemotherapy has led to a median overall survival of nearly four years for patients with a specific type of advanced lung cancer. This marks the longest survival benefit ever recorded in a global trial for this condition, solidifying Tagrisso as a standard-of-care treatment and providing a new benchmark for patient outcomes.

Clinical Trials Healthcare & Pharmaceuticals News Weight-loss Drugs

Wegovy® Shows Superior Cardiovascular Protection Over Tirzepatide in Real-World Study

novo nordisk

The landmark STEER study provides the first head-to-head real-world comparison of the cardiovascular benefits of Wegovy® and tirzepatide. In a study of over 21,000 adults with obesity and established cardiovascular disease, Wegovy® (semaglutide 2.4 mg) demonstrated a significantly greater reduction in the risk of heart attack, stroke, and death compared to tirzepatide.